Journal Article Summary
The article investigates how the use of combination oral contraceptives (COCs) affects thrombin generation, specifically focusing on a measure called endogenous thrombin potential (ETP). This topic is important because the risk of venous thromboembolism (VTE), a serious condition where blood clots form in veins, increases shortly after starting COCs. Understanding how COCs influence blood clotting factors can help in assessing the risks associated with their use, especially during the initial months.
In this study, 17 women aged 18 to 35 participated, providing multiple blood samples during their first cycle of a specific COC containing ethinyl estradiol (EE) and levonorgestrel (LNG). The researchers measured changes in thrombin generation over time, finding significant increases in ETP levels within just a few days of starting the contraceptive. By the end of the cycle, ETP levels were notably higher than baseline, indicating a heightened risk of clotting. Interestingly, the study found no correlation between the levels of EE or LNG in the participants' blood and the changes in ETP, suggesting that other factors may influence thrombin generation.
The study has limitations, including a small sample size and a focus on only a few hemostatic variables. These findings are preliminary and should not be used to make clinical recommendations. Patients using COCs should discuss any concerns about VTE risk and blood clotting with their healthcare providers, especially if they have other risk factors for clotting disorders. Further research is needed to explore the relationship between COC use and thrombin generation more comprehensively.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Westhoff Carolyn L., Pike Malcolm C., Cremers Serge, Eisenberger Andrew, Thomassen Stella, Rosing Jan. Endogenous Thrombin Potential Changes during the First Cycle of Oral Contraceptive Use. Contraception 2017. DOI: 10.1016/j.contraception.2017.01.001. PMID: 28088496. PMCID: PMC5466838.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
